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In Brief
CDK4/6 inhibitors are potent inhibitors of
cell cycle that are employed clinically.
Franco et al. report that the inhibition of
CDK4/6 in pancreatic cancer models
reprograms metabolism through a
pathway involving the RB tumor
suppressor and MTOR activation. These
findings demonstrate specific metabolic
adaptations to this class of therapeutic
agents and delineate vulnerabilities for
future therapeutic intervention.
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Due to loss of p16ink4a in pancreatic ductal adeno-
carcinoma (PDA), pharmacological suppression of
CDK4/6 could represent apotent target for treatment.
In PDA models, CDK4/6 inhibition had a variable ef-
fect on cell cycle but yielded accumulation of ATP
and mitochondria. Pharmacological CDK4/6 inhibi-
tors inducecyclinD1protein levels; however,RBacti-
vation was required and sufficient for mitochondrial
accumulation. CDK4/6 inhibition stimulated glyco-
lytic and oxidative metabolism and was associated
with an increase in mTORC1 activity. MTOR and
MEK inhibitors potently cooperate with CDK4/6 inhi-
bition in eliciting cell-cycle exit. However, MTOR inhi-
bition fully suppressed metabolism and yielded
apoptosis and suppression of tumor growth in xeno-
graftmodels. Themetabolic statemediatedbyCDK4/
6 inhibition increases mitochondrial number and
reactive oxygen species (ROS). Concordantly, the
suppression of ROS scavenging or BCL2 antagonists
cooperated with CDK4/6 inhibition. Together, these
data define the impact of therapeutics on PDA meta-
bolism and provide strategies for converting cyto-
static response to tumor cell killing.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) has a 5-year survival of
only6% (Saif, 2013; Vincent et al., 2011). This dire prognosis is
due to multiple clinical features of the disease, including diag-
nosis at late stage and ineffective systemic therapies (Paulson
et al., 2013). Therefore, there is significant energy directed at
delineating biological features of PDA that could be exploited
for therapeutic intervention.
One of the hallmark genetic events in PDA is loss of the
CDKN2A/2B tumor suppressor locus (Maitra and Hruban,
2008). This locus encodes endogenous CDK4/6 inhibitors that
are particularly relevant in the context of KRAS-driven tumors,Csuch as PDA (LaPak and Burd, 2014; Witkiewicz et al., 2011).
Oncogenic KRAS can induce a senescent-like growth arrest
state in cells (Serrano et al., 1995, 1997). The execution of
this phenotype is mediated by p16ink4a encoded by CDKN2A
that blocks the activity of CDK4/Cyclin D and CDK6/Cyclin D
complexes (Serrano et al., 1995; Witkiewicz et al., 2011). This
leads to the suppression of RB phosphorylation and concomi-
tant inhibition of cell-cycle progression through the suppression
of E2F-mediated transcription (Chicas et al., 2010). Highly selec-
tive drugs that phenocopy features of p16ink4a function would
be expected to have potency in PDA (Asghar et al., 2015). While
such drugs have some degree of effect in established PDA
cell lines (Franco et al., 2014; Heilmann et al., 2014; Liu and
Korc, 2012; Witkiewicz et al., 2015a), resistance can develop
quickly, thereby necessitating the use of combination therapeu-
tic approaches.
Although the underlying mechanisms remain unclear, cell
division is coordinated with metabolic functions. First observed
in yeast, cell-cycle entry is associated with increased cellular
mass and the accumulation of energetic metabolites required
for cell division (Cai and Tu, 2012). In PDA,much of themetabolic
circuitry is subservient to mutant KRAS, which drives a complex
reprogramming of glycolytic, oxidative and non-canonical (e.g.,
macropinocytosis) metabolic pathways in concert with tumori-
genic proliferation (Bryant et al., 2014; Sousa and Kimmelman,
2014). Key downstream effectors include MEK and MTOR
signaling pathways that engage multiple distal features of meta-
bolism through transcriptional and translational regulatory pro-
grams (Laplante and Sabatini, 2009, 2012; Viale et al., 2014;
Ying et al., 2012). The interface of cell-cycle regulatory factors
with metabolism is similarly complex and varied (Lopez-Mejia
and Fajas, 2015). For example, Cyclin D1, which is a requisite
activator of CDK4/6, has been shown to act in a transcriptional
role to coordinate metabolism and mitochondrial function
(Wang et al., 2006). Additionally, at a cellular and organismal
level CDK4/6 activity plays important roles in controlling gluco-
neogenesis and responsiveness to insulin (Lopez-Mejia and
Fajas, 2015). RB has been shown to bind to mitochondria and
regulate apoptotic functions (Hilgendorf et al., 2013), while E2F
has been shown to drive mitochondrial-dependent apoptosis
in Drosophila (Ambrus et al., 2013; Benevolenskaya and Frolov,
2015). Interestingly, in fibroblastic models RB loss is associatedell Reports 14, 979–990, February 9, 2016 ª2016 The Authors 979
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with increased glutamine utilization (Clem and Chesney, 2012;
Reynolds et al., 2014), and loss of RBF has been associated
with altered glutamine catabolism in Drosophila (Nicolay et al.,
2013). Recent studies have shown that loss of RB can lead to
decreased oxidative phosphorylation and more dependency
on glycolytic metabolism (Nicolay et al., 2015; Va´raljai et al.,
2015). Consonantly, E2F1 and RB in tissue can provide a critical
node of regulation between proliferation and metabolic activity
(Blanchet et al., 2011; Lopez-Mejia and Fajas, 2015). Since
metabolic features of cancer are progressively emerging as a
target for therapeutic intervention, these findings supported a
direct interrogation of how pharmaceutical CDK4/6 inhibitors
impinge on tumor metabolism and the ability to selectively target
that metabolic state.
RESULTS
CDK4/6 Inhibition Yields Increased Mitochondrial Mass
via RB
In order to address the role of CDK4/6 inhibition in PDA, three cell
models were utilized. These models contain classic genetic fea-
tures of PDA (Franco et al., 2014) but exhibit differing cell-cycle
inhibition with pharmacological suppression of CDK4/6 activity
(Figure S1). While many therapeutic agents that target KRAS
signaling suppress metabolism, we observed that CDK4/6 inhi-
bitionwith PD-0332991 resulted in increased cellular complexity,
which is an indirect surrogate of increased organelles and meta-
bolic functions within the cytoplasm (Figure 1A). Concordantly,
CDK4/6 inhibition was accompanied by an increase in ATP levels
(Figure 1B) and an increase in mitochondrial mass in multiple cell
lines (Figures 1C and 1D; Figure S1). Because these effects
could represent a specific feature of PD-0332991 as opposed
to CDK4/6 inhibition, two other specific CDK4/6 inhibitors
(LEE-11 and LY2853219) were employed and exhibited similar
increased MitoTracker staining (Figure S1). Transmission elec-
tron microscopy confirmed the numerical increase in mito-
chondria in cells treated with CDK4/6 inhibitors (Figure 1E).
CDK4/6 inhibitors are known to inhibit cell cycle (Asghar et al.,
2015) but also exert two biochemical effects that are potentially
germane to tumor metabolism. Notably, CDK4/6 inhibitors will
lead to the accumulation of Cyclin D1, which has the capacity
to impact cell biology through non-catalytic functions (LambFigure 1. CDK4/6 Inhibition Leads to Mitochondria Accumulation in an
(A) Representative flow cytometry histogram displaying cellular complexity on th
(B) Relative ATP levels from cells treated with control or PD-0332991 for 120 hr. T
was determined by t test (**p < 0.01, ***p < 0.001).
(C) Confocal fluorescence imaging of mitochondria (62.53) in the indicated cells
(D) Flow cytometry histograms showing comparison of MitoTracker red fluoresc
(E) Representative transmission electron microscope micrograph of control and P
from counting high-power fields and the average and SD are shown. The statisti
(F) Flow cytometry histograms showing comparison of MitoTracker red fluoresc
knockdown.
(G) Quantitation of MitoTracker red intensity following treatment with PD-0332991
are shown. The statistical comparison to vehicle control was determined by t tes
(H) Flow cytometry histograms showing comparison of MitoTracker red fluoresce
(I) H&E staining, immunohistochemistry for (Ki67) (scale bar, 100 mm), and fluores
xenograft EMC43.
See also Figure S1.
Cet al., 2003), and CDK4/6 inhibition results in the suppression
of RB phosphorylation (Dean et al., 2010; Fry et al., 2004)
(Figure S1). Using RNAi-mediated knockdown (Figure S1), Cyclin
D1 depletion had little effect onmitochondrial accumulation (Fig-
ure 1F). In contrast, the knockdown of RB1 partially reverted the
accumulation of mitochondria (Figure 1F) and decreased cellular
complexity (FigureS1). Additionally,wedefined rarecasesofPDA
that exhibit endogenous RB loss (Witkiewicz et al., 2015b). Using
a cell line derived from such a case (EMC7310), we observed that
the increase in mitochondrial mass was dependent on RB
(FigureS1). Furthermore, employingaconstitutively activeconsti-
tutively active RB allele refractory to phosphorylation (PSM.7-LP)
(Knudsen andWang, 1997) indicated RB activity was sufficient to
induce theaccumulationofmitochondria in amanner comparable
to PD-0332991 (Figure 1G). It has recently been shown that RB
can associatewithmitochondria (Hilgendorf et al., 2013). Howev-
er, in the presence of the CDK4/6 inhibitor, RBwas solely nuclear
as determined by immunofluorescence microscopy (Figure S1).
Inparallelwith theseestablishedcell lines, PD-0332991 treatment
of a low passage patient-derived PDA cell line elicited a similar
increase in MitoTracker (Figure 1H). To determine whether these
effects were observed in vivo, the matched xenograft model
derived from the same patient was treated with PD-0332991
for 8 days. This treatment elicited potent suppression of Ki67,
consistent with the established role for CDK4/6; and as observed
in cell lines, there was an increase in mitochondria (Figure 1I).
Reprogramming of Metabolism with CDK4/6 Inhibition
To determine the effect of increased mitochondria number on
metabolism, oxygen consumption was evaluated as a measure
of increased oxidative phosphorylation. As shown in Figure 2A,
there was a substantial increase in oxidative phosphorylation
with CDK4/6 inhibition. Analysis of metabolite levels in culture
media indicated that PD-0332991 treatment resulted in a
significant increase in glucose and glutamine consumption.
Correspondingly, there was enhanced glutamate secretion as
a product of glutamine metabolism, and increased lactate efflux
as a measure of the end product of glycolysis (Figure 2B).
Consistent with the increase in lactate production, there was
a significant increase in media acidification (Figure 2C). These
features were recapitulated with LEE-011 and LY2853219, indi-
cating that increased metabolism is a general feature of CDK4/6RB-Dependent Fashion
e x axis for cells treated with PD-0332991 for 120 hr.
he average and SD are shown, and the statistical comparison to vehicle control
treated with PD-0332991 for 120 hr (scale bar, 20 mm).
ence of the control versus PD-0332991-treated cells.
D-0332991-treated PL5 cells (scale bar, 1 mm). Quantification of mitochondria
cal comparison to vehicle control was determined by t test (***p < 0.001).
ence of the control versus PD-0332991-treated cells following CCND1 or RB
or transduction of the constitutively active RB allele 7-LP. The average and SD
t (*p < 0.05, **p < 0.01).
nce of the control versus PD-0332991-treated cells in the EMC43 cell model.
cence (scale bar, 200 mm) imaging (TOM20/Vimentin/DAPI) of patient-derived
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inhibition (Figure S2). Metabolomic analysis was performed in
conjunctionwith universally labeled 13C-glucose and 13C-gluta-
mine tomonitor metabolic flux. These analyses showed increase
in glycolytic intermediates (i.e., glucose 6-phosphate, fructose
1,6-bisphosphate, pyruvate, and lactate) that were predomi-
nantly derived from glucose as expected (Figure 2E). For TCA
metabolites (i.e., malate, fumarate, succinate, and alpha-keto-
glutarate), there were also significant increases in metabolite
levels (Figure 2F). Flux analysis indicated that these metabolites
were principally derived from glutamine; therefore, the majority
of mitochondrial-derived metabolism is fueled by glutamine in
these models (Figure 2G). Starving cells of either glutamine or
glucose significantly reduced viability (Figures 2H and 2I). How-
ever, pretreatment with CDK4/6 inhibitors protected selectively
against the effect of acute glucose withdrawal, suggesting that
enhanced glutamine metabolism was sufficient to rescue the
reliance on glucose. Similarly, CDK4/6 inhibition limited the
acute toxicity of mitochondrial inhibitors phenformin and rote-
none (Figure S2). These findings underscore the possibility that
the metabolic status of CDK4/6-treated cells could impact on
tumor biology and therapeutic sensitivities.
CDK4/6 Inhibition Drives MTOR Pathway Activation
Given the significance of signaling pathways in regulating
metabolism, we assessed how CDK4/6 inhibition influences
the levels of 217 protein and phospho-proteins by reverse phase
protein array (RPPA) analysis (Tibes et al., 2006) (Figure 3A).
Interestingly, there were very few significant changes in protein
abundance mediated by CDK4/6 inhibition. In terms of down-
regulated proteins, phosphorylated RB and E2F targets
(e.g., Cyclin B1) were downregulated as expected (Figure 3A).
In contrast, the phosphorylation of ribosomal protein S6 at
Ser235/236 was uniquely observed to be significantly increased
with CDK4/6 inhibition (Figure 3A). Immunoblotting confirmed
the increased phosphorylation of S6, an MTOR complex 1
(TORC1) substrate, and also increased phosphorylation of RSK
at Ser 389 (Figure 3B). In contrast, there was no increase in either
ERK or AKT phosphorylation (Figure 3B). To determine if this
signaling feature of CDK4/6 inhibition is observed in vivo, tumor
sections from xenografts treated with PD-0332991 were stained
for Ki67 and phosphorylated S6 and showed the expectedFigure 2. CDK4/6 Inhibition Leads to Metabolic Reprogramming
(A) Oxygen consumption rate (OCR) of PL45 and Capan2 cell lines either contro
(B) Quantification of media glucose and glutamine uptake, and glutamate and
treatment. The average and SD are shown. The statistical comparison to vehicle
(C) Extracellular acidification rate (ECAR) in cells treated with or without PD-0332
(D) Relative fold change of glycolytic intermediates Glucose 6P; Fructose 1,6BP; p
are shown. The statistical comparison to vehicle control was determined by t tes
(E) Flux analysis of cell populations treated with universally labeled 13C-glucose
relative average abundance and SD of differing mass species.
(F) Relative fold change of TCA intermediates alpha-ketoglutare, citrate, malate,
vehicle control was determined by t test (**p < 0.01).
(G) Flux analysis of cell populations treated with universally labeled 13C-glucose
relative average abundance and SD of differing mass species.
(H) Quantification of cell viability following acute glucose or glutamine withdrawa
was determined by t test (*p < 0.05).
(I) Representative images of crystal violet stained cells following either glutamine
See also Figure S2.
Creduction in Ki67 and a significant increase in S6 phosphoryla-
tion (Figure 3C). Similar results were observed in PDX models
(Figure S3). Together, these data indicate that MTOR signaling
is activated with the inhibition of CDK4/6. Parallel analysis of
transcriptional pathways was performed on cells treated with
PD-0332991 for 5 days. This treatment resulted in the downregu-
lation of multiple genes involved in cell-cycle control, consistent
with the expected suppression of RB phosphorylation (Figures
3D and S3). However, a large number of genes were significantly
upregulated (Figure 3D), and gene set enrichment analysis
identified the induction of genes associated with glycolysis, lyso-
some, pyruvate metabolism, fatty acid metabolism, and PPAR
signaling (Figures 3D and S3). Importantly, many of these pro-
cesses are activated downstream of MTOR (Laplante and Saba-
tini, 2009), suggesting this signaling pathway is associated with
CDK4/6-inhibition-mediated metabolic effects.
Canonically, the activation state of MTOR is regulated by
PI3K/AKT/TSC pathway, amino acid availability, lysosomes,
and the appropriate milieu of regulatory proteins (Laplante and
Sabatini, 2012). In the analysis of gene expression data and
RPPA, there was no evidence for the activation of PI3K/AKT or
the abundance of TORC1 or TORC2 subunits or regulatory pro-
teins (not shown). However, there was a rapid (24 hr) increase in
lysosomes that preceded the increase in mitochondria (Fig-
ure S3). Immunofluorescence analysis demonstrated that the
majority of MTOR in PDA models is associated with lysosomal
structures, and treatment with CDK4/6 inhibitors increased lyso-
some-associated MTOR (Figure S3). These data suggest that
TORC1 complex activation is occurring. Additionally, there was
an accumulation of amino acids as determined by mass spec-
trometry (Figure S3). Consistent with the supposition that amino
acids play an important role downstream from RB, depletion of
amino acids blocked the induction of MTOR activity with
CDK4/6 inhibition (Figure S3). Together, these data suggest
that CDK4/6 inhibition triggers an energetic feedforward loop
that engages MTOR signaling for metabolic reprogramming.
MTOR and MEK Inhibitors Exhibit Distinct Endpoints
with CDK4/6 Inhibition
To determine the functional interaction between CDK4/6 inhi-
bition and signaling pathways, a panel of agents that inhibitl or treated with PD-0332991.
lactate production from the indicated cell lines with or without PD-0332991
control was determined by t test (*p < 0.05, **p < 0.01, ***p < 0.001).
991.
yruvate; and lactate as determined bymass spectrometry. The average and SD
t.
(solid bars) or universally labeled 13C-glutamine (stippled bars). Bars show the
and fumarate. The average and SD are shown. The statistical comparison to
(solid bars) or universally labeled 13C-glutamine (stippled bars). Bars show the
l. The average and SD are shown. The statistical comparison to vehicle control
or glucose withdrawal (scale bar, 200 mm).
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Figure 3. CDK4/6 Inhibition Leads to the Induction of MTOR Activity and Downstream Effects on Metabolism
(A) Quantification of reverse phase protein array (RPPA) data. The log-fold change of proteins abundancewith PD-0332991 treatment is displayed as a function of
the 217 protein species detected on the array. RPPA data for selected proteins and phosphoproteins is shown, with the average abundance and SD. The
statistical comparison to vehicle control was determined by t test (*p < 0.05, **p < 0.01).
(B) Immunoblotting was performed for the indicated proteins in cells treated with the indicated pathway selective inhibitors.
(C) Immunohistochemical analysis of xenograft tumors treated with lactate control or PD-0332991 for 8 days. Representative images of Ki67 and pS6 (S235/236)
are shown (scale bar, 100 mm).
(D) Gene expression profiling was performed on Capan 2 cells treated with control or PD-0332991 for 120 hr. The heatmap shows genes passing a 1.5-fold
p < 0.05 cutoff. Representative genes falling into selected gene set enrichment categories are shown in the heatmap.
(legend continued on next page)
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PI3K, MTOR, and MEK was employed. Consistent with prior
work (Franco et al., 2014), we observed potent cooperation of
MTOR and MEK inhibitors with CDK4/6 inhibitors; however,
there was little influence of PI3K selective inhibitors (Figure 3E).
Interestingly, there were significant differences in the
morphology of cells treated with MEK versus MTOR inhibitors
(Figure 3F). Since both MTOR and MEK inhibitors cooperated
to invoke similar levels of cell-cycle inhibition, the associated
influence on metabolism was evaluated. MEK inhibition further
augmented the impact of CDK4/6 inhibition on oxidative
metabolism including increased mitochondrial mass, cellular
complexity, and enhanced OCR (Figures 3G, 3H, and S3). How-
ever, MEK inhibition selectively inhibited glycolysis (Figure 3I). In
contrast, combined CDK4/6 and MTOR inhibition resulted in the
suppression of both glycolytic and oxidative functions, as was
most evident in terms of the mitochondrial accumulation that
was completely suppressed (Figures 3G–3I and S3). These com-
bined findings suggest a pathway through which the selective
activation of RB in the presence of oncogenic signals enables
the further accumulation of MTOR signaling and resultant stimu-
lation of metabolism, while MEK is predominantly required for
the maintenance of glycolytic metabolism.
Combination Treatments with CDK4/6 Inhibitors Result
in Durable Therapeutic Response
The distal effects of the combination of CDK4/6 inhibition with
MTOR or MEK inhibition were evaluated. MEK in combination
with CDK4/6 inhibition enforced profound cell-cycle inhibition
(Figure S4) and a potent cytostatic effect with evidence of
induced senescence (SA-b-Gal) (Figure 4A). In contrast,
MTOR inhibition suppressed senescence, but resulted in the in-
duction of cell death (Figure 4B). This apoptotic cell death could
not be reversed by supplementation with methyl-pyruvate or
alpha-ketoglutarate, which directly supports mitochondrial
metabolism (Figure S4). The treatment yielded suppression of
tumor cell proliferation over > 2 weeks in culture (Figure 4C).
Importantly, in PL5 xenograft models while both PD-0332991
and the PI3K/MTOR inhibitor BEZ235 exhibit some single agent
activity, the combination was significantly more potent for the
suppression of tumor cell growth and proliferative index (Fig-
ures 4D, 4E, and S4). These data were further confirmed
through the use of an independent orthotopic model (PL45),
where the combined treatment both suppressed tumor growth
and reduced metastatic burden in this highly aggressive model
(Figures 4E and S4).
Selectively Targeting ROS and Mitochondria in the
Presence of CDK4/6 Inhibition
A high level of oxidative phosphorylation is believed to repre-
sent a liability to tumor cells, due to the role of mitochondria(E) Quantification of BrdU positive cells following 24 hr treatment with dual PI3
Deforolimus), and MEK (AZD-6244) inhibitors alone and in combination with PD
statistical comparison to single agent treatment was determined by t test (*p < 0
(F) Bright-field images of PD-0332991, AZD-6244, and Torin 1 and combination
(G–J) Quantification of mitochondria (G), OCR (H), ECAR (I), and ATP (J) levels from
and SD are shown. The statistical comparison to control was determined by t te
See also Figure S3.
Cin apoptosis and generation of reactive oxygen species
(ROS). Indeed, treatment of the PDA models with CDK4/6 in-
hibitor resulted in increased total ROS and mitochondria-
derived ROS (Figure 4F and S4). However, one of the key tran-
scriptional responses to CDK4/6 inhibition includes the accu-
mulation of genes involved in peroxisome biosynthesis and
the expression of ROS scavengers including hemeoxygenase
1 (HO-1) and catalase (CAT) (Figure S4). The knockdown of
either HO-1 or CAT elicited a significant reduction in PDA cell
growth and cooperated with CDK4/6 inhibition (Figures 4G,
4H, and S4). These findings suggest that increased utilization
of mitochondria is balanced by antioxidant pathways in the
context of CDK4/6 inhibition. Interestingly, not all perturbations
of ROS regulatory processes cooperated with CDK4/6 inhibi-
tion. Notably, the glutathione inhibitor BSO failed to further in-
crease ROS levels above CDK4/6 inhibition and similarly did
not cooperate with CDK4/6 inhibition in these models
(Figure S4).
An alternative means to exploit mitochondria is through
mobilization of BH3-containing proteins. It is known that ROS
and other stresses, including CDK inhibition, can effectively limit
the expression of MCL1 or modify its activity (Brunelle et al.,
2007; Thomas et al., 2010). Cells treated with PD-0332991
exhibited a marked suppression of the high-mobility form of
MCL1 (Figure S4). To determine whether this was related to
increased sensitivity to mitochondrial-mediated apoptosis, the
BCL2 inhibitor ABT-737 was employed (Oltersdorf et al., 2005).
Cells that had been pretreated with PD-0332991 and exhibited
an accumulation of mitochondria were selectively sensitive to
ABT-737 that elicited apoptotic cell death (Figures 4J–4L and
S4). Importantly, the pretreatment with CDK4/6 inhibition also
elicited long-term suppression of proliferation in combination
with ABT-737 (Figure 4L). Together, these data indicate that
the mitochondria andmetabolic features of CDK4/6 treated cells
could be selectively exploited to yield a synthetic approach to
cancer treatment.
DISCUSSION
There has been an ever-increasing appreciation of the impor-
tance of metabolism in cancer and as a target for therapeutic
intervention (Sousa and Kimmelman, 2014; Vander Heiden,
2011). In parallel, it is becoming evident that CDK4/6 inhibitors
will be utilized in multiple clinical settings either singly or in com-
bination (Asghar et al., 2015; Dickson, 2014).
The impact of CDK4/6 inhibition on tumor metabolism is
distinct from other targeted agents that have been evaluated
in PDA models. In general, therapeutic agents against the
KRAS signaling pathway suppress features of mitogenic
signaling and result in attenuation of specific facets ofK/MTOR (BEZ235), PI3K (BKM120, BYL719), mTOR (Torin, Everolimus, and
-0332991 treatment. The average BrdU incorporation and SD are shown. The
.05, **p < 0.01, ***p < 0.001).
treated cells (scale bar, 100 mm).
cells treated with the indicated drugs and combinations. The average signals
st (*p < 0.05, **p < 0.01, ***p < 0.001).
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metabolic activity (Lyssiotis et al., 2013; Vander Heiden, 2011;
Viale et al., 2014; Ying et al., 2012). This can occur either
through the attenuation of glycolysis as observed with MEK in-
hibitors, or a general diminution of metabolic function as re-
ported with MTOR inhibitors. Increased metabolic activity
observed in PDA models with CDK4/6 inhibition was surprising,
since in different settings CDK4 and Cyclin D1 expression or
RB loss enhance metabolic functions associated with prolifera-
tion (Clem and Chesney, 2012; Lopez-Mejia and Fajas, 2015;
Reynolds et al., 2014). For example, in Drosophila CDK4 is
well-established to drive cellular growth by activating metabolic
pathways (Datar et al., 2000). In spite of these prior studies,
recent work has shown that RB loss is selectively associated
with a diminution of oxidative phosphorylation and increased
sensitivity to mitochondrial poisons (Nicolay et al., 2015).
Therefore, our findings suggest that RB activation by CDK4/6
inhibition essentially drives this process in reverse and acti-
vates mitochondrial function. Correspondingly, such treated
cells are actually less sensitive to glucose withdrawal and mito-
chondrial poisons.
The finding that tumors treated with CDK4/6 inhibitors main-
tain a high metabolic rate has significant clinical implications.
Such a state could represent a potential liability as the treated
tumor cells are metabolically charged for cell division, and
cessation of the CDK4/6 inhibition could elicit rapid cell-cycle
progression. In yeast models the accumulation of cell mass
and energetics can drive subsequent rounds of proliferation
under non-ideal conditions (Cai and Tu, 2012). This could in
part represent one of the challenges of employing CDK4/6 in-
hibitors as single agents in the clinic. Importantly, the meta-
bolic features observed here in preclinical models are consis-
tent with imaging from clinical trials. In the analysis of single
agent PD-0332991 in mantle cell lymphoma, the FLT-PET
signal, which measures thymidine utilization, was suppressed,
while the signal for FDG-PET was maintained, suggesting the
tumors treated in this fashion maintain significant metabolic
activity (Leonard et al., 2012).Figure 4. Selective Cooperation with CDK4/6 Inhibition for Enhancing
(A) Quantification of SA-b-gal positive cells following the indicated treatments.
comparison to control was determined by t test (**p < 0.01, ***p < 0.001).
(B) Quantification of apoptotic cells following the indicated treatments. The avera
control was determined by t test (***p < 0.001).
(C) Colony formation was assessed at the indicated times by crystal violet staini
(D) Tumor volume of PL5 xenografts following treatment with BEZ235, PD-0332
volume and SD are plotted, and the statistical comparison versus vehicle treated
(E) Representative Ki-67 immunohistochemistry of the PL5 treated xenografts (s
(F) Tumor volume of orthotopically implanted PL45 cells that were treated with th
vehicle treated control are shown.
(G) Representative histograms showing fluorescence of total ROS in the presenc
(H) Surviving cells following HO-1 or CAT knockdown in the absence or presen
relative to transfected controls. The statistical analysis to the RNAi control was d
(I) Colony outgrowth of knockdown cells alone or in combination with PD-03329
(J) Fold change in fraction of apoptotic cells pretreated with PD-0332991 for the in
number of apoptotic cells and standard SD are shown. The statistical analysis to
(*p < 0.05).
(K) Impact of PD-0332991 pretreatment on sensitivity to ABT-737. The average an
(*p < 0.05, **p < 0.01).
(L) Prolonged treatment with ABT-737 of control or PD-0332991 pretreated and
See also Figure S4.
CMechanistically, CDK4/6 inhibitors are unique as they sup-
press proliferation downstream from many of the oncogenic
signaling pathways that stimulate both metabolism and cellular
proliferation (Asghar et al., 2015; Dickson, 2014). As shown
here, the activity of effectors distal to KRAS is maintained
following the exposure to CDK4/6 inhibitor. Additionally, we
find MTOR signaling is stimulated with suppression of CDK4/6
activity in the PDA cells and tumor models studied. MTOR
engages a signaling program downstream from nutrient avail-
ability to stimulate metabolism leading to cell-cycle progression
(Laplante and Sabatini, 2009, 2012) and therefore is generally
antagonistic to the cytostatic effect of CDK4/6 inhibition. We
observe the induction of multiple gene expression programs
known to be downstream of MTOR including glycolysis, lyso-
some biogenesis, fatty acid metabolism, and PPAR signaling
(Laplante and Sabatini, 2009). Presumably this elevated MTOR
signaling in concert with a suppression of cell-cycle progression
is sufficient to enhance the metabolic features observed in the
PDA cultures and tumors observed. One of the key questions
is how CDK4/6 impacts MTOR. MTOR activation occurs as a
consequence of amino acid availability and lysosomal localiza-
tion (Sancak et al., 2008). Interestingly, CDK4/6 inhibition yielded
a rapid accumulation of lysosomes, and metabolomics analysis
showed increased amino acid pools. These data suggest an
energetic feedforward loop, wherein CDK4/6 inhibition yields
increased metabolic activity that is further exaggerated by
MTOR activation that mediates downstream effects on meta-
bolism and mitochondria. Critically, MTOR inhibition can sup-
press effects of CDK4/6 inhibitor on metabolism; thus, MTOR
activity is required for metabolic reprogramming induced by
CDK4/6 inhibition. In spite of these findings, the exact signaling
through which CDK4/6 and RB controls metabolism remains
under study, as does the potential context dependence beyond
the PDA models studied here.
In pancreatic and other solid tumors, the efficacy of CDK4/6 in-
hibitors will likely be dependent on combination therapies. Thus,
defining means to selectively capitalize on the metabolic statusTherapeutic Effect
The average number of senescent cells and SD are shown. The statistical
ge number of apoptotic cells and SD are shown. The statistical comparison to
ng. Representative images are shown.
991, and the combination was measured as a function of time. The average
control is shown by t test (*p < 0.05, **p < 0.01).
cale bar, 100 mm).
e indicated agents. The average volume, SD, and statistical comparison to the
e versus absence of PD-0332991.
ce of PD-0332991 was determined. Bars show the average surviving fraction
etermined by t test (*p < 0.05, **p < 0.01, ***p < 0.001).
91. Representative images are shown.
dicated period of time, followed by acute treatment with ABT-737. The average
single agent versus combination with PD-0332991 was determined by t test
d SD are shown. The statistical comparison to control was determined by t test
stained for crystal violet.
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imparted byCDK4/6 inhibition is particularly pertinent. Due to the
withdrawal from the cell cycle, CDK4/6 inhibitors have an antag-
onistic function related to select chemotherapies (Roberts et al.,
2012), further underscoring the need for rational combinatorial
approaches. In breast cancer models, PI3K inhibitors potently
cooperate with CDK4/6 inhibition (Vora et al., 2014). However,
this combination has a relatively modest effect in PDA models.
In contrast, MEK and MTOR inhibition potently cooperate with
CDK4/6 inhibition (Franco et al., 2014; Heilmann et al., 2014).
In spite of similar effects on cell-cycle suppression, MEK and
MTOR inhibition have distinct effects on metabolism and
biology. As has been previously published, MEK activity is
particularly relevant for maintaining glycolytic function in PDA
models (Ying et al., 2012). MEK inhibitors function in concert
withCDK4/6 inhibition to enhance the accumulation ofmitochon-
dria and oxidative phosphorylation, eliciting a pronounced cell-
cycle arrest with features of senescence. In contrast, MTOR
inhibitors restricted glycolytic metabolism and oxidative phos-
phorylation induced by CDK4/6 inhibition and yielded cell death
and suppression of tumor growth. While potent cooperation is
observed in several cell and xenograft models, a concerted effort
across multiple patient-derived models will be required to deter-
mine the fractionof tumors thatwouldbeexpected tobesensitive
to such interventions in the clinic.
Targeting metabolism or other conserved features of cell
biology represents a challenge in establishing a therapeutic
index (Galluzzi et al., 2013). In contrast with other agents, the in-
crease in tumor associated mitochondria and ROS could repre-
sent a unique target for tumors treated with CDK4/6 inhibitors
(Sabharwal and Schumacker, 2014). Inhibitors of antioxidants
are being considered as cancer therapies due to the established
increase in ROS production bymany tumors (Gorrini et al., 2013).
We observed that both depletion of catalase or hemoxygenase-1
cooperated with CDK4/6 inhibition. Similarly, the high levels
of mitochondria in principle could yield increased sensitivity
to mitochondrial-driven cell death mediated by agents such as
ABT-737. Thus, these studies provide potential avenues for
considering converting the cytostatic nature of CDK4/6 inhibitors
to cytotoxicity.
Given the recent FDA approval of CDK4/6 inhibitors, their use
will become progressively commonplace. Understanding both
canonical cell-cycle and metabolic features of treatment expo-
sure will be important for defining preferred combination strate-
gies and capitalizing on tumor biology.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
The established cell lines Capan2, PL45, and PL5 were cultured as previ-
ously described (Franco et al., 2014). Primary cell lines (EMC43, EMC18128,
and EMC7310) were cultured in keratinocyte serum-free (KSF) medium with
0.2 ng/ml EGF and 30 mg/ml bovine pituitary extract (Invitrogen) on collagen-
coated plates. Cells were transfected with RNAi or transduced with adenovi-
ruses as previously described (Baek et al., 2014; Franco et al., 2014). Detailed
descriptions are provided in the Supplemental Experimental Procedures.
Mitochondria and Lysosome Analysis
Staining of mitochondria with MitoTracker and LysoTracker was as previously
described (Baek et al., 2014). The transmission electronmicroscopy and stain-
ing is described in detail in the Supplemental Experimental Procedures.988 Cell Reports 14, 979–990, February 9, 2016 ª2016 The AuthorsImmunoblotting, Immunohistochemistry, and Immunofluorescence
For immunoblotting total cell extracts were prepared, resolved by SDS-PAGE,
and transferred to immobilon membranes. The following primary antibodies
were utilized from the indicated vendors: pRB (S780), total RB, p-p70s6k
(T389), pAKT (S473), pERK (Y204), pS6 (S235/236), and MTOR were from
Cell Signaling Technology; VDAC and Vimentin were from Abcam; GAPDH,
LAMP-2, Cyclin A, Catalase, and Tom20 antibodies were from Santa Cruz;
Cyclin D1 was from Neomarkers; and HMOX1 was fromMillipore. Immunohis-
tochemistry and immunofluorescence staining were performed as described
in detail in the Supplemental Experimental Procedures.
Metabolic Analysis
Glucose and glutamine uptake and lactate and glutamate production was as-
sessed using a biochemistry analyzer (BioProfile Basic 4 Analyzer; Nova
Biomedical). Measurement of oxygen consumption rate and extracellular acid-
ification rates were performed using a Seahorse Bioscience XF24 Extracellular
Flux Analyzer. Metabolite levels were determined using a Q Exactive benchtop
Orbitrap mass spectrometer equipped with an Ion Max source and a HESI II
probe, which was coupled to a Dionex UltiMate 3000 UPLC system (Thermo
Fisher Scientific). A detailed description of these approaches is provided in
the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.12.094.
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